BBP News and Press, Virtus LifeSci Biotech Products From 07/14/22

Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phas...

As companies adjust to inflation, rising interest rates, and a likely economic slowdown, investors are struggling to compute future earnings and the impact on stock valuations. Broadening the sources of stability can help diversify risk and return potential. Geopolitical risk and ...

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such ...

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...

Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...

Why the economy, practically speaking, may already be in recession. Why defensive sectors may be worth a closer look in the current environment. Market sentiment might be bearish, but that doesn't mean there aren't opportunities. Aggressive moves by central banks...

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...

Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023. Results from the p...

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...